AHA 2024 - Subodh Verma shares the results of a sub-analysis from the SELECT trial in patients who had a prior history of CABG.
Semaglutide reduces MACE in patients with obesity or overweight and prior CABG

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Prof. Subodh Verma is cardiac surgeon at St. Michael's Hospital and professor at the University of Toronto in Toronto, ON, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 19 November 2024
Overview
AHA 2024 - Subodh Verma shares the results of a sub-analysis from the SELECT trial in patients who had a prior history of CABG.
Educational information
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Faculty
Prof. Subodh Verma is cardiac surgeon at St. Michael's Hospital and professor at the University of Toronto in Toronto, ON, Canada.
Disclaimer
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
Release date: 19 November 2024
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
Diagnosis and Management of Metastatic PDAC
Chemotherapy Strategies for Metastatic PDAC
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
A Practical Guide to Prescribing in HF
Clinical Conundrums in ARIA: Differential Diagnoses and Potential Pitfalls in ARIA Evaluation
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?